AI Summary
An adaptive trial for glioblastoma treatment showed no improvement in patient survival, but has the potential to quickly identify effective therapies.
An innovative phase 2 clinical trial designed to find new potential treatments for glioblastoma has reported initial results. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.